Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Top Cited Papers
- 3 March 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 15 (4), 424-435
- https://doi.org/10.1016/s1470-2045(14)70027-0
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive LymphomaJournal of Clinical Oncology, 2012
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upAnnals Of Oncology, 2012
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBlood, 2012
- Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2007
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleBlood, 2004
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984
- No Initial Therapy for Stage III and IV Non-Hodgkin's Lymphomas of Favorable Histologic TypesAnnals of Internal Medicine, 1979